munity was established, a steady state ensued in which the number of sensitized lymphocytes in the spleen was similar, regardless of the route or dose of vaccination. Actively immunized animals controlled intravenous and subcutaneous challenge infections, regardless ofthe method ofvaccination. However, pulmonary challenge was resisted most efficiently by mice immunized by the pulmonary route. Adoptive immunity was well expressed in the spleen only, but the lungs were no more deficient in this regard than the footpad. It is suggested that enhanced immunity in the lungs depends on a population of resident sensitized lymphocytes.
There is ample published evidence that the route of immunization with BCG determines the level of delayed tuberculin hypersensitivity (DTH) and resistance to reinfection with tubercle bacilli. Subcutaneous/intradermal inoculation favors the development of tuberculin DTH, compared with pulmonary (P) and intravenous (i.v.) immunization (14, 16) . On the other hand, although animals infected by the P, i.v., or subcutaneous routes are resistant to i.v. challenge with virulent tubercle bacilli, resistance to pulmonary challenge is observed only after P or i.v. immunization (1, 3, 4, 17, 24) .
The latter observations in particular are disturbing because they do not conform to the demonstrated efficacy of intradermal immunization with BCG in protecting humans against pulmonary tuberculosis (22) . Moreover, since the cells that confer long-term antituberculosis immunity are long-lived, recirculating, small lymphocytes (21) , it is puzzling that these cells should be less available to combat pulmonary infection than infection at any other site.
Earlier studies have been limited to the response of actively immunized animals to i.v. or P challenge. The use of actively immunized animals incurs the problem of nonspecific resistance that is found to a greater or lesser extent in animals immunized with BCG (5, 18) . In such animals, it is impossible to determine how much of the observed resistance to reinfection is attributable to specific or nonspecific effects. The comparison of the lungs and spleen as sites of tuberculosis infection also creates some difficulties. The spleen is the major central lymphoid organ through which the recirculating lymphocytes traverse (13, 15) . The lung parenchyma contain small foci of lymphoid tissue (26) but cannot be regarded as lymphoid organs to which lymphocytes "home." Consequently, it could be argued that the lungs are at a disadvantage to the spleen in their content of immunocompetent cells.
The purpose of this study was to critically reevaluate certain variables that may influence the induction and expression of anti-tuberculosis immunity. These factors include the dose of BCG and its route of administration, and the expression of immunity in the spleen, the lungs, and one other peripheral site, the hind footpad (FP). The problem of nonspecific resistance has been circumvented by testing the ability of spleen cells from immunized mice to confer antituberculosis immunity upon nonimmune recipients (19 Irradiation. Before challenge with RlRv and transfer of spleen cells, all recipient mice and their controls were exposed to 500 rads of total body irradiation from a "Cs source (19) .
Spleen cels. Spleens were removed from donor mice and teased apart, and the dissociated cells were washed in ammonium chloride/tris(hydroxymethyl)aminomethane buffer to lyse erythrocytes (6 (Fig. 1) . Repeated experiments revealed considerable inter-experimental variation in the development and decay of DTH, but there were certain consistent features ( Fig. 1 and 4 ). Only the larger doses of BCG resulted in perceptible DTH, which was maximal at 3 to 4 weeks and then waned rapidly. LHFP immunization resulted in a biphasic response, and the state of hypersensitivity was sustained for a longer period of time. In all experiments, the level of DTH 3 months after immunization was trivial, regardless of the route and dose of BCG.
The ability of spleen cells of vaccinated mice to confer adoptive immunity upon syngeneic recipients is illustrated in Fig. 2 . There was a small but highly significant ( (Fig. 3) . No apparent growth of BOG occurred in the LHFP, probably because the large inoculum induced a rapid immune response that prevented multiplication (18) . As will become evident later, smaller inocula of BOG did multiply in the FP (Fig. 6 to 8 ). After i.v. infection, BOG multiplied in the spleen for 4 weeks and then slowly decreased in number. Growth of BOG in the lungs after aerosol infection was substantial, and large numbers of viable orgaism were present in this organ throughout the course of the experiment.
The development of tuberculin DTH in these mice is shown in Fig. 4 18, 1977 uniform capacity to transfer anti-tuberculosis immunity within 8 weeks of immunization. In the next series of experiments, mice were vaccinated with BCG, l03 i.v. (Fig. 6 ), 106 LHFP (Fig.  7 ), or 1iO P (Fig. 8) . Eight weeks later, when the ability of spleen cells to transfer immunity (Fig. 6 to 8) .
The effects of spleen-cell transfer will be considered first. As in earlier experiments, spleen cells from the different groups of immunized donors provided excellent protection (P < 0.01) against i.v. infection with RlRv, and immunity was manifest within 2 weeks of challenge. The extent of adoptive immunity in the spleen was usually less than that in actively immunized donors (P < 0.01) at 2 weeks ( Fig. 6 and 7 ), but at 4 weeks there was no difference between the counts in the two types of mice ( Fig. 6 to 8 ).
The expression of adoptive immunity in the RHFP and lungs was defective as compared with the spleen. Spleen cells from i.v.-and Pvaccinated mice did not confer resistance in either of these sites at 2 weeks after challenge or in the RHFP at 4 weeks ( Fig. 6 and 8) . A modest degree of protection, 0.41 loglo unit (P < 0.05), was expressed in the lungs at 4 weeks in recipients of cells from i.v.-immunized mice (Fig.  6 ). Spleen cells from LHFP-immunized mice were more effective. They conferred resistance in the RHFP at 2 weeks (P < 0.05) and 4 weeks (P < 0.01) and in the lungs at 4 weeks (P < 0.01) (Fig. 7) . It is notable that this particular batch of cells also conferred the highest level of adoptive immunity in the spleen (Fig. 6 to 8 ).
Before reinfection with RlRv, donor mice of each group were killed, and viable counts of residual BCG from the immunizing inoculum were made in the spleen, RHFP, and lungs ( Fig.  6 to 8 ). Each group of donor spleens contained approximately 103 viable BCG at the time of challenge and an undetectably low (<102) number of organisms in the RHFP. Less than 102 viable BCG were isolated from the lungs of LHFP-or i.v.-immunized mice, but approximately 105 BCG were present in the lungs of Pimmunized mice. This population of BCG was approximately 10-fold greater than the challenge inoculum of RlRv (Fig. 8) .
Turning now to the expression of active immunity, the anti-mycobacterial mechanism was most effective in the RHFP, where growth of the organisms was completely suppressed and there was a net decrease of viable organisms by 2 weeks (Fig. 6 to 8 ). There was limited growth of RlRv in the spleens during the first 2 weeks after challenge, but the inhibition of growth was highly significant (P < 0.01) relative to normal mice. The control of challenge infection in the RHFP and spleen was closely similar in all groups of vaccinated mice. On the other hand, the ability to control P infection varied with the route of immunization. Only mice vaccinated by the P route inhibited the growth of RlRv in the lungs (P < 0.01) within 2 weeks of reinfection (Fig. 8) , but all donor mice controlled the infection (P < 0.01) by 4 weeks (Fig. 6 to 8) .
DISCUSSION
An examination of the induction of immunity after BCG vaccination has been made by the method of adoptive transfer of resistance with lymphoid cells. This system has been shown to depend on an immunologically specific population of T-lymphocytes and circumvents the problem of nonspecific resistance that exists in the actively immunized donors (19, 20) . It was found that the rapidity of onset of immunity was a function of the size of the immunizing inoculum, a conclusion that had been inferred in earlier work (18) . The influence of inoculation route was less apparent, but it appeared that immunity appeared first after FP, then i.v., and finally P vaccination. More impressive than the rate of induction of immunity was the consistent, stable level at which the numbers of sensitized lymphocytes in the spleen achieved equilibrium. Within 2 months of immunization, this equilibrium was such that the transfer of adoptive immunity with 5 x 107 spleen cells was closely similar regardless of the dose and route of vaccination. This steady state reflects a homeostatic mechanism that compensates for a 1,000-fold variation in inoculum size, and is the more remarkable because the initial lymphoproliferative response to living BCG is very much dependent on the dose (21) .
Tuberculin hypersensitivity after immunization with BCG was a function of dose and route of administration. The highest levels of DTH were obtained with 106 LHFP, followed by 106 i.v., 103 i.v., and lastly 104 P. The levels of DTH varied considerably between experiments. It is worth noting that the fluctuation in DTH is in marked contrast to the consistency with which spleen cells conferred immunity.
This study has confirmed the observations of others that P immunization with living BCG engenders a greater resistance to subsequent P reinfection than does i.v. or subcutaneous vaccination (1, 3, 4, 17, 24) . Admittedly, the i. 18, 1977 is injected, an oil-in-water emulsion. The oil droplets, into which antigen is incorporated, localize in the lungs due to embolism of the pulmonary capillaries and induce extensive granulomatosis (1, 29) . Similarly, the system of Myrvik (25) also induces chronic pulmonary granulomatosis. By contrast, i.v. injection of living BCG in saline deposits 90% of the inoculum in the liver, 10% in the spleen, and only 1% in the lungs (10, 11) . Hence, the i.v. injection of mycobacterial antigens in oil and aerosol infection with BCG both constitute vaccination by the P route.
A number of explanations for the association between P immunization and pulmonary resistance will now be considered. Ribi and co-workers have shown that the protective action of his nonliving vaccines is a function of the granulomatosis that is produced, measured as increase in lung weight (2, 23) . The implication of this observation is that the increased resistance to P infection is due to nonspecific resistance exerted by the macrophages participating in the pulmonary granulomas. An analogous situation exists in animal that have been immunized with living BCG, in whom resistance to reinfection at a particular site is associated with the persistence of live vaccinating organisms at that site (17) . These observations are supported by this study, in which mimal resistance to reinfection in the lung was expressed in mice carrying a substantial number of BCG (>105) in that organ at the time of challenge. The association between resistance at a given site and persistence of immuniing organisms is not invariable. In this study, resistance to reinfection was highest in the RHFP, from which BCG was never isolated. Whereas it is not contended that activated macrophages in the lungs or other organs do not restrain the growth of challenge organism, it is doubtful whether such action fully accounts for the experimental results. The growth of RlRv in the lungs of i.v.-and FP-immunized mice is unimpeded for at least 14 days (Fig. 6  and 7 ), whereas the effective duration of nonspecific resistance is measured in as many hours (28) . It (7, 9) . If this were so, P and FP infection might be expected to generate lymphocytes that produced better protection at the homologous than the heterologous site. The results of the cell transfer experiments provide no support for this notion. Cells from P-immunized mice did not confer preferential protection upon the lungs of recipients. Paradoxically, cells from i.v.-and FP-immunized mice were more effective in this regard. Moreover, actively immunized mice combated i.v. and FP challenge with equal facility, regardless of the immunization route.
It is proposed that the sheer proximity of sensitized lymphocytes to the implanted, homologous, challenge organisms results in a brisker anamnestic response, because time is gained that would otherwise be spent in recruiting a sufficient number of sensitized lymphocytes from the circulation into the site of challenge. Such tissue lymphocytes may correspond to the sessile memory cells of humoral immunity (12, 31) and may share identity with the lung cells that can produce migration-inhibiting factor after immunization via the respiratory tract (8, 14, 27, 33) . The rapid expression of cell-mediated immunity in the spleen is attributable in part to the migration through that organ of recirculating lymphocytes in which anti-tuberculosis immunity is vested (21) , obviating the need for further recruitment. Moreover, regardless of the route of immunization, a significant number of living BCG eventually reach the spleen, where they generate tuberculoid granulomas.
It has been argued that adoptive immunity cannot be expressed in the lungs (34) , the implication being that there is defective migration of sensitized lymphocytes into this organ. The data in Fig. 7 in different organs (Table 1 ). There appears to be a rational explanation for the relatively good resistance of the spleen. The intrinsic susceptibility of the lungs and FP is high and low, respectively, and currently there is no good reason for this discrepancy. The resistance of a susceptible organ like the lung can be increased by appropriate immunization, but only at the cost of inducing substantial ganulomatous disease. There was no association between antituberculosis immunity, active or adoptive, and the level of tuberculin hypersensitivity.
